BMB Reports : eISSN 1976-670X

Cited by CrossRef (12)

  1. Chi-Hyun Ahn, Kyu-Young Oh, Bohwan Jin, Won Woo Lee, Jihoon Kim, Hyun-Ji Kim, Dong-Guk Park, Neeti Swarup, Kunal Chawla, Mi Heon Ryu, Uk-Kyu Kim, Su-Jung Choi, Hye-Jung Yoon, Seong-Doo Hong, Ji-Ae Shin, Sung-Dae Cho. Targeting tumor-intrinsic PD-L1 suppresses the progression and aggressiveness of head and neck cancer by inhibiting GSK3β-dependent Snail degradation. Cell Oncol. 2022
    https://doi.org/10.1007/s13402-022-00748-8
  2. Lili Song, Shikai Liu, Sufen Zhao. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway. Bioengineered 2022;13:11240
    https://doi.org/10.1080/21655979.2022.2064205
  3. Myong Hak Ri, Juan Ma, Xuejun Jin. Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer. Journal of Ethnopharmacology 2021;281:114370
    https://doi.org/10.1016/j.jep.2021.114370
  4. Guangyuan Li, Susmita Ghosh, JuMe Park, Hyunsu Shin, Mamatha Garige, Gregory Reaman, Carole Sourbier. A mouse pancreatic organoid model to compare PD-L1 blocking antibodies. mAbs 2022;14
    https://doi.org/10.1080/19420862.2022.2139886
  5. Mamatha Garige, Susmita Ghosh, Alexis Norris, Guangyuan Li, Sarah Poncet, Chao-Kai Chou, Wells W. Wu, Rong-Fong Shen, Carole Sourbier. PD-L1 Mediates IFNγ-Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma. Front. Oncol. 2022;12
    https://doi.org/10.3389/fonc.2022.858379
  6. Elena Levantini, Giorgia Maroni, Marzia Del Re, Daniel G. Tenen. EGFR signaling pathway as therapeutic target in human cancers. Seminars in Cancer Biology 2022;85:253
    https://doi.org/10.1016/j.semcancer.2022.04.002
  7. Je-Jung Lee, So Young Kim, Songhee H. Kim, Seoyeon Choi, Bin Lee, Jeon-Soo Shin. STING mediates nuclear PD-L1 targeting-induced senescence in cancer cells. Cell Death Dis 2022;13
    https://doi.org/10.1038/s41419-022-05217-6
  8. Ahmed Halima, Winston Vuong, Timothy A. Chan. Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. 2022;132
    https://doi.org/10.1172/JCI154945
  9. Jihyun Moon, Yoo Min Oh, Sang-Jun Ha. Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications. BMB Rep 2021;54:403
    https://doi.org/10.5483/BMBRep.2021.54.8.054
  10. Abishek Chakkaravarthi Moorthy, Vindu Srivastava. Systematic review on PDL-1 exression in human cancer. IJPO 2022;9:298
    https://doi.org/10.18231/j.ijpo.2022.072
  11. Yunxia Ma, Rumyana Marinkova, Miljana Nenkov, Lai Jin, Otmar Huber, Jürgen Sonnemann, Natália Peca, Nikolaus Gaßler, Yuan Chen. Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt/β-Catenin Pathway in Human Non-Small Cell Lung Cancer. IJMS 2022;23:11031
    https://doi.org/10.3390/ijms231911031
  12. Mariana Cooke, Xuyao Zhang, Suli Zhang, Evgeniy Eruslanov, Priti Lal, Reba E. Daniel, Michael D. Feldman, Martin C. Abba, Marcelo G. Kazanietz. Protein Kinase C Alpha is a Central Node for Tumorigenic Transcriptional Networks in Human Prostate Cancer. 2022;2:1372
    https://doi.org/10.1158/2767-9764.CRC-22-0170